本帖最后由 老马 于 2012-1-13 21:20 编辑 % R: p% C1 E( B. U: }
8 T$ g9 _/ c) c3 G2 y/ m5 g爱必妥和阿瓦斯丁的比较* ` I4 Z9 a$ M" C9 |1 N
# u% Y" s9 Q: I4 D$ e7 ~* r
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/. ]* ]3 [& K1 @; }0 |& L: d
* m, B3 D2 x0 r/ D& G
- J J0 ]2 @* z5 V) o( e) B! d- e
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/. z' p6 f1 E9 R1 G/ [% D
==================================================
P9 [- l1 d3 KOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
5 j% p' |" o1 R4 e- ?3 @9 kPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
6 L8 b- v' W9 [+ qResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; l* [4 R/ Z- z
|
显身卡
: E$ }/ k' p( v) J3 w2 Q9 }
